Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

At present, biological agents have emerged as cornerstone systemic therapies for psoriasis, particularly IL-17 monoclonal antibodies due to their efficacy in patients with moderate-to-severe psoriasis ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...